Author

Vadim Shirinkin

Observed names: V. B. Shirinkin, V. Shirinkin, В. Б. Ширинкин, Ширинкин В.Б.

Institution: Orenburg Regional Clinical Oncology Center

Observed institutions: Federal Almazov North-West Medical Research Centre, Orenburg Regional Clinical Oncology Center

ORCID: 0000-0002-2475-9500

Observed ORCID: 0000-0002-2475-9500

OpenAlex ID: A5031211585

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

2018 · Kohei Shitara, Mustafa Özgüroğlu, et al. · The Lancet · 1,338

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

2020 · Sandra M Swain, David Miles, et al. · The Lancet Oncology · 990

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial

2022 · Ying Cheng, Liang Han, et al. · JAMA · 540

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

2018 · Michael Friedlander, Ursula Matulonis, et al. · British Journal of Cancer · 190

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

2014 · X. Pivot, J. Gligorov, et al. · Annals of Oncology · 188

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

2017 · Rebecca Kristeleit, Irina Davidenko, et al. · Gynecologic Oncology · 102

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

2017 · J. Gligorov, B. Ataseven, et al. · European Journal of Cancer · 49

Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

2017 · Charlie Gourley, Michael Friedlander, et al. · Journal of Clinical Oncology · 25

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial

2026 · Jingjing Liu, Liang Han, et al. · JAMA Oncology · 5

112RO Subsequent anti-cancer therapy (SACT) of patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in ATHENA-MONO/GOG-3020/ENGOT-ov45

2026 · E. Prendergast, V. Salutari, et al. · ESMO Open · 1

BRCA-associated ovarian cancer in the russian patient population. Analysis of the non-interventional study Ovatar

2024 · T. T. Tikhomirova, A. S. Tyulyandina, et al. · Malignant tumours

Опыт выполнения комбинированных операций с реконструктивно-пластическим компонентом передней брюшной стенки в онкогинекологии

2020 · В. Б. Ширинкин, Elena Dikareva, et al.

122 Reconstructive plastic surgery using fasciocutaneous flaps in the surgical treatment of vulvar cancer (193 cases within the 1995-2015 time period)

2020 · E. Dikareva, E. Ulrikh, et al. · International Journal of Gynecological Cancer

Works count: 14

Citation count: 3,428

H-index: 8

I10-index: 8